Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Publication
, Conference
Prebet, T; Gore, SD; Sun, Z; Greenberg, PL; Juckett, M; Malick, L; Smith, MR; Paietta, E; Czader, M; Gabrilove, J; Erba, HP; Tallman, MS
Published in: BLOOD
November 19, 2010
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 19, 2010
Volume
116
Issue
21
Start / End Page
264 / 265
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
52nd Annual Meeting of the American-Society-of-Hematology (ASH)
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Prebet, T., Gore, S. D., Sun, Z., Greenberg, P. L., Juckett, M., Malick, L., … Tallman, M. S. (2010). Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. In BLOOD (Vol. 116, pp. 264–265). Orlando, FL: AMER SOC HEMATOLOGY.
Prebet, Thomas, Steven D. Gore, Zhuoxin Sun, Peter L. Greenberg, Mark Juckett, Lisa Malick, Mitchell R. Smith, et al. “Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905.” In BLOOD, 116:264–65. AMER SOC HEMATOLOGY, 2010.
Prebet T, Gore SD, Sun Z, Greenberg PL, Juckett M, Malick L, et al. Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. In: BLOOD. AMER SOC HEMATOLOGY; 2010. p. 264–5.
Prebet, Thomas, et al. “Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905.” BLOOD, vol. 116, no. 21, AMER SOC HEMATOLOGY, 2010, pp. 264–65.
Prebet T, Gore SD, Sun Z, Greenberg PL, Juckett M, Malick L, Smith MR, Paietta E, Czader M, Gabrilove J, Erba HP, Tallman MS. Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. BLOOD. AMER SOC HEMATOLOGY; 2010. p. 264–265.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 19, 2010
Volume
116
Issue
21
Start / End Page
264 / 265
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
52nd Annual Meeting of the American-Society-of-Hematology (ASH)
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology